A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor


Phoenix/Scottsdale, Ariz.

Trial status:

Open for Enrollment

Why is this study being done?

Subjects will be followed for one year after first study drug injection. This is the primary study period. Subjects will be followed for 4.5 years after completion of the primary study to assess long-term safety of the vaccine.

Who is eligible to participate?

Inclusion Criteria: - CMV negative subject having received a CMV seropositive kidney (living or deceased) - Subject started valganciclovir or ganciclovir within 10 days of transplant and has received it through Randomization. Exclusion Criteria: - Subject is planned to undergo a course of CMV-specific prophylactic therapy with antiviral drugs with a duration of greater than 100 days. - Subject has received from one month prior to transplant or is planning to receive CMV immunoglobulin. - Subject has had CMV viremia or CMV disease from time of transplant until time of Randomization.

Last updated:




IRB Number: